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Effectiveness research that assesses the impact of health
interventions on patient outcomes is confronted with many
methodological challenges. Although designing valid stud-
ies of effectiveness may be more complex than determining
efficacy in highly controlled research environments, the
hope is that comparative effectiveness research (CER) e
if done wellewill better inform health care decisions to im-
prove patient outcomes.
The Agency for Healthcare Research and Quality
(AHRQ), through its Effective Health Care program, spon-
sored a fourth symposium on research methods for CER
and patient-centered outcomes research (PCOR) in June
2012 to address a selection of issues arising in CER, com-
plementing earlier AHRQ-funded CER Methods Symposia
[1e3]. The focus of the 2012 symposium was on original
research, methodological insights, or advances arising from
the conduct of CER, and how CER can better support
health care decision-making. Methodologists and other re-
searchers were invited to present innovations in research
methods relevant to CER; specifically, methods that can ad-
dress some of the underlying differences in the results of
randomized efficacy trials and observational effectiveness
studies conducted in routine health care settings. Research
presented at the symposium was subsequently developed by
the authors into manuscripts based on relevant feedback
from symposium participants. Authors submitted manu-
scripts for review by the editorial team and qualified man-
uscripts were subsequently peer reviewed by external
experts. The following sections provide an overview of
the papers that were presented and accepted for publication
in this supplement.2. Comparative effectiveness research (CER)/Patient-
centered outcomes research (PCOR) implementations
Choudhry and Shrank present design and implementa-
tion issues from a novel, pragmatic cluster randomized trial
embedded in a commercial insurance claims data system
[4]. The study compares the effect of a financial incentive
(eliminated copayment vs. usual copayment for cardiovas-
cular medications after myocardial infarction) within an ex-
isting payment system. The expectation was that financial0895-4356  2013 Elsevier Inc.
http://dx.doi.org/10.1016/j.jclinepi.2013.05.012
Open access under CC BY-NC-ND license.incentives will improve medication adherence, yielding im-
proved clinical outcomes. The Post-Myocardial Infarction
Free Rx Event and Economic Evaluation (MI FREEE) trial
provides a valuable exploration of the challenges and ben-
efits of conducting a pragmatic trial. Despite the limitations
imposed by the design, studies conducted in this way are
potentially powerful approaches to evaluating health care
interventions because research is conducted within an exist-
ing health care delivery system. As a result, study results
are directly applicable to patients and providers in that sys-
tem, and may be generalizable to other similar systems.
Many operational challenges of the approach are described
to help researchers understand common issues encountered
when applying this design.
Wu et al. underline the importance of adding patient-
reported outcomes to electronic health records and illustrate
how straight-forward collection of routine data can provide
a rich resource for CER [5]. They advocate incorporating
patient-reported outcome measures into widely used elec-
tronic health record systems and using these measures for
both clinical care and effectiveness research. Electronic
health record add-on programs can be used with computer-
ized patient-reported outcome measures, including Patient
Reported Outcomes Measurement Information System
(PROMIS) computer adaptive tests developed by the Na-
tional Institutes of Health (NIH). Three converging trends
are identified and a framework offered for integrating them:
greater patient centeredness and adaptability of patient-
reported outcomes; personalization of electronic health re-
cords; and patient-oriented CER. Given the current national
emphasis on patient-centeredness, the authors argue that
this is an opportune time to align the many stakeholders
in health care to gather support for using electronic health
records as a major CER data source.
N-of-1 trials are seen as the ultimate personalization of
CER because they offer immediate implementation of trial
findings into the process of delivering care. Duan et al.
summarize the conduct and value of N-of-1 trials for clini-
cians, researchers, and health care organizations [6]. The
authors discuss how such trials help clarify the roles of in-
dividual and collective clinical experience in medical
decision-making. These trials become important weapons
in the CER and PCOR methodological armamentarium
and effective clinical tools to inform personalized treatment
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By permitting direct estimation of individual treatment ef-
fects, they offer the possibility of finely graded, individual-
ized care, enhanced therapeutic precision, and improved
patient outcomes. However, success may be strongly influ-
enced by how well these trials can be integrated into mod-
ern delivery systems, and electronic health records may
play an important role in that process.3. Comparative effectiveness research (CER) chal-
lenges in mental health
CER is particularly challenging but rewarding in mental
health. Blanco et al. highlight the challenges in CER for
psychiatric treatments [7]. Research questions often go be-
yond simple head-to-head comparisons in the general pop-
ulation, seeking to assess comparative effectiveness in
patient populations with comorbid medical conditions,
comparing many nuanced non-pharmacological therapies,
or evaluating methods to improve access and retention in
minority populations. The authors argue that clinical trials
should retain their important role in CER in cases of highly
prevalent disorders, large expected effect sizes, difficult-to-
reach populations, sequential treatments, and stepped-care
algorithms. Substantial attention should be paid in choosing
appropriately between clinical trials and observational stud-
ies because it is important to allocate research resources
carefully to inform key treatment decisions. Often a combi-
nation of complementary study types is called for.
Kane et al. focus on the comparative effectiveness of
long-acting injectable versus oral antipsychotic medications
for relapse prevention in schizophrenia, focusing on medi-
cation adherence and rehospitalization [8]. This case study
summarizes and compares the methodology of different
study types and what these studies add to the evidence base.
The authors show how the results of long-acting injectable
studies differ considerably depending on design, and the va-
riety of questions being asked and answered are carefully
dissected here. The authors conclude that the parallel-
group randomized controlled trial is not necessarily the
gold standard for assessing the effectiveness of long-
acting injectables. A large simple trial might be more
informative.4. Studying the effectiveness of health care delivery
system changes
Changes in health care delivery systems are themselves
subject to effectiveness evaluation, but may also create ex-
tra variation in treatment choice that can be used to study
the effectiveness of individual products and therapies. Dore
et al. utilize a study of erythropoietin stimulating agents in
end-stage renal disease patients to compare different
methods of effect estimation [9]. They estimate different
causal effects of erythropoietin-stimulating agents on6-month and 1-year survival in end-stage renal disease:
a) a "natural experiment" with a policy shift through
a switch to bundled payments in end-stage renal disease
care, using a ‘‘difference-in-difference’’ metric, b) instru-
mental variable analysis, as well as c) a propensity score
analysis. The authors compare the estimates and, for each
analysis, dissect the specific causal contrasts and assump-
tions on which causal inference rested.
Also in the setting of anemia treatment in end-stage re-
nal disease patients, Ellis and Brookhart examine the chal-
lenges of estimating the effect of treatment (iron
supplementation) when they are closely correlated with
a concurrent treatment (erythropoiesis-stimulating agent)
[10]. If only one treatment is of interest, then including
the other treatment in the propensity score model as a con-
founder may yield more stable estimates of the effect of in-
terest. If the joint treatment effect is of interest, extreme
inverse probability of treatment weights may need to be
addressed by restricting the sample, exploring limited treat-
ment plans, or through other means. This paper demon-
strates the value of presenting both relative and absolute
effect measures in CER, particularly when studying multi-
ple outcomes with varying incidence rates. It also provides
a summary of analytic methods used in comprehensive
evaluation of safety and effectiveness in terms of acute,
short-term, and long-term events.
Branas et al. report an effectiveness-maximizing ap-
proach for geographically locating emergency care re-
sources [11]. The authors use simulations of response
time as a proxy for trauma outcomes. The location of
trauma centers and helicopter depots affects how rapidly se-
verely injured patients can access trauma center care, which
has implications for survival. These methods may be useful
in other settings, such as planning for other emergency ser-
vices, trauma care, or the location of new hospitals.5. Analytic issues in comparative effectiveness re-
search (CER)
Secondary data describing utilization and outcomes in
routine care without perturbing the system may impose
limits on many design aspects that investigators seek to
control (e.g., standardized measurements). However, they
also give rise to unanticipated analytic opportunities that
can be exploited for CER.
The paper by Walker on the deleterious effect of match-
ing on provider in CER examines an often overlooked dif-
ference between randomized trials and observational
researchethe value of matching at the level of the provider
(or block randomization in trials) [12]. Determinants of
treatment in observational studies are either instruments
or confounders. Control for instruments amplifies the
bias induced by unmeasured confounders. The following
variables are often considered instruments or near-
instruments: physician, practice group, hospital, calendar
time, formulary, and other administrative constraints.
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increase rather than decrease bias from unmeasured con-
founding. This is not the case in block-randomization,
whose purpose is to reduce bias by standardizing measure-
ments within a center in addition to the randomization. Al-
though similar in appearance (non-randomized provider
stratification vs. block randomization), their consequences
are quite different.
Brooks et al. demonstrate the use of geographical treat-
ment variation for instrumental variable analyses [13]. Lo-
cal area practice-style measures can be useful, but results
may vary with the size of the local area in terms of both
the extent of treatment variation used in estimation and
the potential risk of confounding. Brooks defines the ‘‘local
area practice style (LAPS)’’ as the instrument. Each pa-
tient’s local area is defined by a fixed number of N patients
surrounding the patient within a 10-minute drive of the pa-
tient’s zip code. Results are sensitive to how many patients
are required by the definition, and may be subject to resid-
ual confounding (when N is too small) or loss of heteroge-
neity in the instrument itself (when is N too large).
Variable selection in propensity score analyses needs
to include all predictors of outcome for valid estimation.
Stuart et al. use prognostic-scores to assess the balance
achieved in propensity score analyses in CER [14]. Using
a prognostic score estimated among the unexposed to com-
pare the underlying outcome risk across treatment groups in
a weighted or matched cohort is described. The more
similar the outcome risk, the more likely confounding is
controlled. Balance measures based on the expected prog-
nosis under one condition (e.g., control) perform particu-
larly well. CER can use the prognostic score-based
balance measure to gauge the success of their propensity
score approach.
The paper by Lendle et al. on targeted maximum likeli-
hood estimation (TMLE) introduces this innovative and
comprehensive approach, adapted to CER [15]. The paper
makes a case for moving beyond the use of simplifying
parametric models for estimating causal parameters. The
flexibility and efficiency of using super-learner techniques
combined with targeted maximum likelihood estimation
may be useful, particularly for the analysis of secondary
data, where the choice and measurement of covariates
and censoring is largely out of the investigator’s control.
In addition to the flexibility in estimating treatment choice
and outcomes, the approach provides efficient estimation of
the effect size. The approach is doubly robust, i.e., even if
either treatment or the outcome model (but not both) are
misspecified, the effect size is validly estimated. An exam-
ple study and appropriate references to the literature will al-
low the reader to explore this exciting and highly promising
data-driven approach to CER analyses.
Neugebauer et al. used super-learning to avoid incorrect
inference from arbitrary parametric assumptions in mar-
ginal structural modeling [16]. Inferences from marginal
structural modeling based on inverse probability weightingfrom electronic health record data are sensitive to paramet-
ric decisions for modeling treatment selection and right-
censoring mechanisms. Super-learning can effectively har-
ness confounding and selection bias by flexibly bundling
multiple existing machine learning algorithms. Erroneous
inferences about clinical effectiveness because of arbitrary
and incorrect parametric assumptions may be reduced
through the use of the super-learning algorithm.
Nelson et al. demonstrate the incorporation of detailed
covariate information in a patient subsample in the setting
of influenza vaccination effectiveness in reducing mortality
[17]. This association is known to be subject to very strong
confounding. The authors augmented self-controlled analy-
ses in longitudinal administrative data with detailed infor-
mation on health state and frailty in a subset of patients.
The validation methods to correct for bias caused by un-
measured confounding will somewhat reduce confounding
via imputation or inverse probability weighting. Selectively
missing vaccination exposure information may explain
parts of the residual bias.6. Design issues in comparative effectiveness research
(CER)
Engaging stakeholders including patients in the design
of CER may ensure that the research will answer questions
relevant to decision-makers. Devine et al. describe how
a PCOR infrastructure was built [18]. The project adminis-
ters patient-reported outcome instruments for research and
clinical care and engages patients through advisory groups,
thus improving patient-centeredness in their research. The
authors apply a recently published conceptual framework
for conducting PCOR to their inaugural pragmatic trial in
peripheral artery disease to describe the usefulness of their
approach.
The paper by Connor et al. on Bayesian Adaptive Trials
for CER makes a strong case for the usefulness of adaptive
trial designs for more efficiently using study resources, max-
imizing patient benefit and minimizing patient risk in CER
[19]. The example study compares three treatment options
in an adaptive trial of anti-epileptic agents. The authors’ in-
novative approach identifies not just the single superior treat-
ment but also the least effective treatment. At the price of
additional planning and closer monitoring of interim findings
required by adaptive designs, they will minimize the number
of subjects needed to answer this question and get patients on
the best treatment as soon as possible.
Time-related biases are an important threat to validity in
the analysis of secondary databases. Mi et al. evaluate the
impact of immortal person-time and time scale in effective-
ness studies of medical devices using implantable
cardioverter-defibrillators as an example [20]. The authors
compared Mantel-Byar, Landmark, and the exclusion
method for handling immortal time bias. The authors also
examined the effect of different time scales (time from
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cation of the various methods. Immortal time bias can be
corrected through design or analysis, but the exclusion
method is biased in favor of the treatment group and should
be avoided in this setting. Most importantly, comparative
effectiveness researchers need to be aware of time-related
biases. Mi et al. demonstrate appropriate ways to address
immortal time.
Overall, methods for CER and PCOR are in a dynamic
phase of develop and testing, particularly methods for
non-randomized treatment comparisons. As new methodol-
ogies begin to penetrate the CER community, including
algorithm-based approaches to causal inference (targeted
maximum likelihood estimation, Super Learner), long-
known principles of bias control may present themselves
in new light. In these exciting times it is important to be
vigilant for both new opportunities and old fallacies.
Sebastian Schneeweissa,*
John D. Seegera
John W. Jacksona
Scott R. Smithb
aDivision of Pharmacoepidemiology
and Pharmacoeconomics
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA, USA
bCenter for Outcomes & Evidence
Agency for Healthcare Research and Quality
Boston, MA, USA
*Corresponding author. Division of Pharmacoepidemiology
and Pharmacoeconomics
Brigham & Women’s Hospital
Harvard Medical School
1 Brigham Circle, Suite 3030
Boston, MA 02120, USA
E-mail address: Schneeweiss@post.harvard.edu
References
[1] Lohr KN. Comparative effectiveness research methods: emerging
methods and policy applications. Med Care 2010;48(6 Suppl):S1e158.
[2] Lohr KN. Comparative effectiveness research methods: emerging
methods and policy applications. Med Care 2007;45(10 Suppl 2):
S1e172.
[3] Schneeweiss S, Smith SR. Methods for developing and analyzing
clinically rich data for patient-centered outcomes research: an over-
view. Pharmacoepidemiol Drug Saf 2012;21(Suppl 2):S1e154.
[4] Choudhry NK, Shrank WH. Implementing randomized effectiveness
trials in large insurance systems. J Clin Epidemiol 2013;66(Suppl 1):
S5e11.[5] Wu AW, Kharrazi H, Boulware LE, Snyder CF. Measure once, cut
twice e adding patient reported outcome measures to the electronic
health record for comparative effectiveness research. J Clin Epide-
miol 2013;66(Suppl 1):S12e20.
[6] Duan N, Kravitz RL, Schmid CH. Single patient (N-of-1) trials:
a pragmatic clinical decision methodology for patient-centered com-
parative effectiveness research. J Clin Epidemiol 2013;66(Suppl 1):
S21e8.
[7] Blanco C, Rafful C, Olfson M. The use of clinical trials in compar-
ative effectiveness research on mental health. J Clin Epidemiol
2013;66(Suppl 1):S29e36.
[8] Kane JM,Kishimoto T, Correll C. Assessing the comparative effective-
ness of long-acting injectable vs. oral antipsychotic medications in the
prevention of relapse provides a case study in comparative effective-
ness research in psychiatry. J Clin Epidemiol 2013;66(Suppl 1):
S37e41.
[9] Dore D, Swaminanthan S, Gutman R, Trivedi AN, Mor V. Different
analyses estimate different parameters of the effect of erythropoietin
stimulating agents on survival in end stage renal disease: a comparison
of payment policy analysis, instrumental variables, and multiple impu-
tation of potential outcome. J Clin Epidemiol 2013;66(Suppl 1):
S42e50.
[10] Ellis AR, Brookhart MA. Approaches to inverse-probability-of-
treatment-weighted estimation with concurrent treatments. J Clin
Epidemiol 2013;66(Suppl 1):S51e6.
[11] Branas C, Wolff CS, Williams JC, Margolis G, Carr BG. Simulating
changes to emergency care resources in comparing system effective-
ness. J Clin Epidemiol 2013;66(Suppl 1):S57e64.
[12] Walker A. Matching on provider is risky. J Clin Epidemiol
2013;66(Suppl 1):S65e8.
[13] Brooks JM, Tang Y, Chapman CG, Cook EA, Chrischilles EA.
What is the effect of area size when using local area practice
style as an instrument? J Clin Epidemiol 2013;66(Suppl 1):
S69e83.
[14] Stuart E, Lee BK, Leacy FP. Prognostic-score based balance mea-
sures for propensity score methods in comparative effectiveness re-
search. J Clin Epidemiol 2013;66(Suppl 1):S84e90.
[15] Lendle SD, Fireman B, van der LaanMJ. Targetedmaximum likelihood
estimation in safety analysis. J Clin Epidemiol 2013;66(Suppl 1):
S91e8.
[16] Neugebauer R, Fireman B, Roy JA, Raebel MA, Nichols GA,
O’Connor PJ. Super learning to hedge against incorrect inference
from arbitrary parametric assumptions in marginal structural model-
ing. J Clin Epidemiol 2013;66(Suppl 1):S99e109.
[17] Nelson JC, Marsh T, Lumley T, Larson EB, Jackson LA,
Jackson ML. Validation sampling can reduce bias in healthcare data-
base studies: an illustration using influenza vaccination effectiveness.
J Clin Epidemiol 2013;66(Suppl 1):S110e21.
[18] Devine EB, Alfonso-Cristancho R, Devlin A, Edwards TC,
Farrokhi ET, Kessler L, et al. A model for incorporating patient
and stakeholder voices in a learning health care network: Washington
State’s Comparative Effectiveness Research Translation Network.
J Clin Epidemiol 2013;66(Suppl 1):S122e9.
[19] Connor JT, Elm JJ, Broglio KR. Bayesian adaptive trials for compar-
ative effectiveness research: an example in status epilepticus. J Clin
Epidemiol 2013;66(Suppl 1):S130e7.
[20] Mi X, Hammill BG, Curtis LH, Greiner MA, Setoguchi S. Im-
pact of immortal person-time and time scale in comparative ef-
fectiveness research for medical devices: a case for implantable
cardioverter-defibrillators. J Clin Epidemiol 2013;66(Suppl 1):
S138e44.
